Published in AIDS Weekly, July 8th, 1996
Nelfinavir mesylate (Agouron Pharmaceuticals Inc.) is the latest entry in what is now a field of four protease inhibitors being tested in combination with nucleoside-analog reverse-transcriptase inhibitors.
Early studies of nelfinavir in combination with stavudine (d4T) in patients with CD4 counts of at least 200 cells/(mu)L and HIV RNA levels of at least 15,000 copies/ml show that the drug decreases HIV RNA by 1.7 to 2.4 log10 and increases CD4 counts by 105 to 133 cells/(mu)L after two months of treatment.
"I think this is an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.